Major depressive disorder with subthreshold hypomanic (mixed) features: A real-world assessment of treatment patterns and economic burden

Journal of Affective Disorders

Volumn 210, Issue , 2017, Pages 332-337

  McIntyre, Roger S ^a   Ng Mak, Daisy ^b   Chuang, Chien Chia ^c   Halpern, Rachel ^d   Patel, Pankaj A ^e   Rajagopalan, Krithika ^b   Loebel, Antony ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^c VERTEX PHARMACEUTICALS   (United States)

^d OPTUM   (United States)

^e KANTAR HEALTH   (United States)

Author keywords

Drug utilization; Health services research; Healthcare administrative claims; Major depressive disorder; Major depressive disorder with mixed features; Mood disorders

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; MOOD STABILIZER; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; NEUROLEPTIC AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; DRUG DEPENDENCE; DRUG USE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; HYPOMANIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIXED MANIA AND DEPRESSION; OUTCOME ASSESSMENT; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; SUBTHRESHOLD HYPOMANIA; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; BIPOLAR DISORDER; COMPLICATION; COST OF ILLNESS; ECONOMICS; MIDDLE AGED; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; BIPOLAR DISORDER; COST OF ILLNESS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SUBSTANCE-RELATED DISORDERS;

EID: 85008714366     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2016.12.033     Document Type: Article

References (28)

1. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders DSM-IV, 4th ed., 1994, American Psychiatric Association, Washington, DC.
2. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR Fourth Edition. 4th ed., 2000, American Psychiatric Publishing, Inc., Washington, DC.
3. American Psychiatric Association, 2013. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5, 5 edition. ed. American Psychiatric Publishing, Washington, D.C.
4. Angst, J., Cui, L., Swendsen, J., Rothen, S., Cravchik, A., Kessler, R.C., Merikangas, K.R., Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am. J. Psychiatry 167 (2010), 1194–1201.
5. Azorin, J.-M., Kaladjian, A., Adida, M., Fakra, E., Belzeaux, R., Hantouche, E., Lancrenon, S., Self-assessment and characteristics of mixed depression in the French national EPIDEP study. J. Affect. Disord. 143 (2012), 109–117, 10.1016/j.jad.2012.05.036.
6. Baldessarini, R.J., Faedda, G.L., Offidani, E., Vázquez, G.H., Marangoni, C., Serra, G., Tondo, L., Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: a review. J. Affect. Disord. 148 (2013), 129–135, 10.1016/j.jad.2012.10.033.
7. Dudek, D., Rybakowski, J.K., Siwek, M., Pawłowski, T., Lojko, D., Roczeń, R., Kiejna, A., Risk factors of treatment resistance in major depression: association with bipolarity. J. Affect. Disord. 126 (2010), 268–271, 10.1016/j.jad.2010.03.001.
8. Faedda, G.L., Marangoni, C., Reginaldi, D., Depressive mixed states: a reappraisal of Koukopoulos’ criteria. J. Affect. Disord. 176 (2015), 18–23, 10.1016/j.jad.2015.01.053.
9. Fiedorowicz, J.G., Endicott, J., Leon, A.C., Solomon, D.A., Keller, M.B., Coryell, W.H., Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am. J. Psychiatry 168 (2011), 40–48, 10.1176/appi.ajp.2010.10030328.
10. Greenberg, P.E., Fournier, A.-A., Sisitsky, T., Pike, C.T., Kessler, R.C., The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J. Clin. Psychiatry 76 (2015), 155–162, 10.4088/JCP.14m09298.
11. Hu, J., Mansur, R., McIntyre, R.S., Mixed specifier for bipolar mania and. Prim. Care Companion CNS Disord., 2014, 16, 10.4088/PCC.13r01599.
12. Ivanova, J.I., Birnbaum, H.G., Kidolezi, Y., Subramanian, G., Khan, S.A., Stensland, M.D., Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder. Curr. Med. Res. Opin. 26 (2010), 2475–2484, 10.1185/03007995.2010.517716.
13. McIntyre, R.S., Soczynska, J.K., Cha, D.S., Woldeyohannes, H.O., Dale, R.S., Alsuwaidan, M.T., Gallaugher, L.A., Mansur, R.B., Muzina, D.J., Carvalho, A., Kennedy, S.H., The prevalence and illness characteristics of DSM-5-defined “mixed feature specifier” in adults with major depressive disorder and bipolar disorder: results from The International Mood Disorders Collaborative Project. J. Affect. Disord. 172C (2015), 259–264, 10.1016/j.jad.2014.09.026.
14. Pacchiarotti, I., Bond, D.J., Baldessarini, R.J., Nolen, W.A., Grunze, H., Licht, R.W., Post, R.M., Berk, M., Goodwin, G.M., Sachs, G.S., Tondo, L., Findling, R.L., Youngstrom, E.A., Tohen, M., Undurraga, J., González-Pinto, A., Goldberg, J.F., Yildiz, A., Altshuler, L.L., Calabrese, J.R., Mitchell, P.B., Thase, M.E., Koukopoulos, A., Colom, F., Frye, M.A., Malhi, G.S., Fountoulakis, K.N., Vázquez, G., Perlis, R.H., Ketter, T.A., Cassidy, F., Akiskal, H., Azorin, J.-M., Valentí, M., Mazzei, D.H., Lafer, B., Kato, T., Mazzarini, L., Martínez-Aran, A., Parker, G., Souery, D., Ozerdem, A., McElroy, S.L., Girardi, P., Bauer, M., Yatham, L.N., Zarate, C.A., Nierenberg, A.A., Birmaher, B., Kanba, S., El-Mallakh, R.S., Serretti, A., Rihmer, Z., Young, A.H., Kotzalidis, G.D., MacQueen, G.M., Bowden, C.L., Ghaemi, S.N., Lopez-Jaramillo, C., Rybakowski, J., Ha, K., Perugi, G., Kasper, S., Amsterdam, J.D., Hirschfeld, R.M., Kapczinski, F., Vieta, E., The international society for bipolar disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am. J. Psychiatry 170 (2013), 1249–1262, 10.1176/appi.ajp.2013.13020185.
15. Pacchiarotti, I., Mazzarini, L., Kotzalidis, G.D., Valentí, M., Nivoli, A.M.A., Sani, G., Torrent, C., Murru, A., Sanchez-Moreno, J., Patrizi, B., Girardi, P., Vieta, E., Colom, F., Mania and depression. Mixed, not stirred. J. Affect. Disord. 133 (2011), 105–113, 10.1016/j.jad.2011.03.037.
16. Patkar, A., Gilmer, W., Pae, C., Vöhringer, P.A., Ziffra, M., Pirok, E., Mulligan, M., Filkowski, M.M., Whitham, E.A., Holtzman, N.S., Thommi, S.B., Logvinenko, T., Loebel, A., Masand, P., Ghaemi, S.N., A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PloS One, 7, 2012, e34757, 10.1371/journal.pone.0034757.
17. Perlis, R.H., Cusin, C., Fava, M., Proposed DSM-5 mixed features are associated with greater likelihood of remission in out-patients with major depressive disorder. Psychol. Med. 44 (2014), 1361–1367, 10.1017/S0033291712000281.
18. Perugi, G., Angst, J., Azorin, J.-M., Bowden, C.L., Mosolov, S., Reis, J., Vieta, E., Young, A.H., BRIDGE-II-Mix Study Group, Mixed features in patients with a major depressive episode: the BRIDGE-II-MIX study. J. Clin. Psychiatry 76 (2015), e351–e358, 10.4088/JCP.14m09092.
19. Popovic, D., Vieta, E., Azorin, J.-M., Angst, J., Bowden, C.L., Mosolov, S., Young, A.H., Perugi, G., Suicide attempts in major depressive episode: evidence from the BRIDGE-II-Mix study. Bipolar Disord. 17 (2015), 795–803, 10.1111/bdi.12338.
20. Smith, D.J., Forty, L., Russell, E., Caesar, S., Walters, J., Cooper, C., Jones, I., Jones, L., Craddock, N., Sub-threshold manic symptoms in recurrent major depressive disorder are a marker for poor outcome. Acta Psychiatr. Scand. 119 (2009), 325–329, 10.1111/j.1600-0447.2008.01324.x.
21. Stensland, M.D., Jacobson, J.G., Nyhuis, A., Service utilization and associated direct costs for bipolar disorder in 2004: an analysis in managed care. J. Affect. Disord. 101 (2007), 187–193, 10.1016/j.jad.2006.11.019.
22. Suppes, T., Silva, R., Cucchiaro, J., Mao, Y., Targum, S., Streicher, C., Pikalov, A., Loebel, A., Lurasidone for the treatment of major depressive disorder with mixed features: a Randomized,. Am. J. Psychiatry, 2015, 10.1176/appi.ajp.2015.15060770.
23. The University of South Florida, 2015. Florida Medicaid Drug Therapy Management Program, sponsored by the Florida Agency for Health Care Administration. 2015 Florida Best Practice Psychotherapeutic Medication Guidelines for Adults.
24. Tunis, S.L., Ascher-Svanum, H., Stensland, M., Kinon, B.J., Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs. PharmacoEconomics 22 (2004), 1–8.
25. U.S. Bureau of Labor Statistics, 2010. Measuring Price Change for Medical Care in the CPI. [WWW Document]. 〈http://www.bls.gov/cpi/cpifact4.htm#1a〉 (accessed 02.10.16).
26. United States Congress, 1996. Health Insurance Portability and Accountability Act of 1996.
27. Verdolini, N., Agius, M., Ferranti, L., Moretti, P., Piselli, M., Quartesan, R., 2015. The state of the art of the DSM-5 “with mixed features” specifier. Sci. World J. 2015. doi: 10.1155/2015/757258.
28. Vieta, E., Valentí, M., Mixed states in DSM-5: implications for clinical care, education, and research. J. Affect. Disord. 148 (2013), 28–36, 10.1016/j.jad.2013.03.007.